ubiquitin isopeptidase inhibitor i, g5

Ubiquitin Isopeptidase Inhibitor I, G5 is a caspase-independent inducer of cell necrosis that induces cell death via the death receptor pathway (IC50 of 1.76 and 1.6 μM in E1A and E1A/C9DN cells, respectively).

GSK-3 Inhibitor 5 (4-Cyanophenacyl bromide) is a ketone derivative that is used as an intermediate in pharmaceuticals and organic synthesis, and inhibits glycogen synthase kinase 3 (GSK-3).

Prostaglandin G H synthase 1 inhibitor (CP 74006) is a selective D5D inhibitor with an IC(50) value of 20 nM.

5-LOX inhibitor (1-(sec-Butyl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one) is one of the impurities of itraconazole, a selective LOX-5 inhibitor.

1-[4-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)piperazin-1-yl]-2-(6-methyl-1-benzofuran-3-yl)ethan-1-one Yes An organic structural unit.

Angiotensin I/II (1-5) is a peptide (ASP-ARG-VAL-TYR-ILE) that contains the amino acids 1-5 and is converted from Angiotensin I/II.

PKM2 inhibitor G is a inhibitor of pyruvate kinase.

AHR Inhibitor I-103 is an aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity used in the study of breast cancer and acute myeloid leukemia.

ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor (IC50: 15.3 nM) that reduces CCl4-induced hepatic fibrosis and exhibits anti-hepatic fibrosis effects.

Protein kinase G inhibitor-2 exhibits antibacterial, antiviral, and antitumor activities.

Thrombin inhibitor 5 (compound 385) is a thrombin inhibitor with IC50 values ranging from 0.1 μM to 1 μM, suitable for venous thromboembolism research[1].

ADAMTS-5 Inhibitor is an inhibitor of ADAMTS-5 with an IC50 of 1.1 µM and can be used in studies about cartilage destruction in arthritis.

Protein kinase G inhibitor-1 is a potent Protein kinase G inhibitor, IC50= 0.9 uM.

PRL-3 Inhibitor I (BR-1) is a phosphatase of regenerating liver 3 (PRL-3) inhibitor which blocks the migration and invasion of metastatic cancer cells.

Topoisomerase II inhibitor 5 (Compound E24) is a DNA topoisomerase II inhibitor with anticancer properties.

Glyoxalase I inhibitor 4 is a potent inhibitor of glyoxalase I (GLO1) (Ki: 10 nM).

Tuberculosis inhibitor 5 (Compound 11i) is a potent antimycobacterial biphenyl analogue and anti-tuberculosis agent with no apparent cytotoxicity.

Topoisomerase I inhibitor 8, a hexacyclic analogue of camptothecin, is also a potent inhibitor of topoisomerase I and is toxic to tumour cells.

Topoisomerase I II inhibitor 3 (compound 7) is a potent dual inhibitor of topoisomerase I (Topo I) and II (Topo II) that inhibits the PI3K Akt mTOR signaling pathway, subsequently inhibiting cell proliferation, invasion, and migration, and inducing apoptosis. This compound has research value in liver cancer.

Topoisomerase I inhibitor 5 is an efficient topoisomerase I inhibitor with an IC50 value, effectively disrupting DNA and inhibiting topoisomerase I activity. It induces apoptosis in MCF-7 cells and arrests the cell cycle at the G1 phase, displaying potency in reversing P-gp-mediated resistance to Adriamycin [1].

N-DMTr-N2-isobutyryl-morpholino-G-5’-O-phosphoramidite is a useful organic compound for research related to life sciences and the catalog number is TNU1600.

Topoisomerase I inhibitor 7 (Compound 8) is a potent Topoisomerase I inhibitor that significantly reduces tumor growth by up to 79% and extends the lifespan of mice bearing P388 lymphoma transplants by 153%.

Topoisomerase I Inhibitor 9 (compound 3d), a specific inhibitor of leishmanial topoisomerase IB, exhibits antileishmanial activity, demonstrating an IC50 value of 34.81μM against L. donovani promastigotes [1].

Human PD-L1 inhibitor I is a peptide ligand that specifically inhibits the interaction between human PD-L1 and human PD-1, exhibiting a KD value of 3.39 μM, indicating its binding affinity. The presence of Human PD-L1 inhibitor I disrupts their binding, thereby attenuating their respective functions.

MMP inhibitor I is a peptide inhibitor of matrix metalloproteinase-1 (MMP-1), MMP-2, and MMP-3 (IC50s = 1.3, 30, and 150 μM, respectively). It is selective for MMP-1, MMP-2, and MMP-3 over the proteases thermolysin, urease, trypsin, α-chymotrypsin, plasmin, and elastase at concentrations up to 4 mM.

ChoKα Inhibitor-5, a sulfur-containing choline kinase inhibitor, effectively inhibits HChoKα1 with an IC50 value of 0.64 μM and induces apoptosis. It is utilized in cancer research [1].

PI3Kγ inhibitor 5 is a potent inhibitor of phosphoinositide 3-kinase γ (PI3Kγ), exhibiting an exceptional IC50 value of 34 nM.

PKI PKA Inhibitor (5-24) is a synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase) (Ki= 2.3 nM) derived from the active site of the skeletal muscle inhibitor protein.1It mimics the protein substrate by binding to the catalytic site through the arginine-cluster basic subsite.1The prominent enzyme-substrate interaction site occurs where PKA catalytic subunit residues Tyr235and Phe239form a sandwich-like structure with residue Phe10of PKI (5-24).2

N-Trityl-N2-isobutyryl-morpholino-G-5'-O-phosphoramidite is a Nucleoside Derivative - Morpholino nucleoside; Phosphoramidite.

FAK inhibitor 5 is a novel allosteric FAK inhibitor, with IC50 values in the low micromolar range.

Microtubule inhibitor 5 (compound 17f) is a highly potent cytotoxic agent that inhibits microtubule function, exhibiting a substantial cytotoxic effect on NCI-H460 cells with an IC50 value of 154.5 nM. Additionally, this compound demonstrates excellent cell permeability [1].

Topoisomerase I inhibitor 4 (compound 7a) is a potent inhibitor of topoisomerase I activity, effectively inhibiting the proliferation of various cancer cell lines, including HepG2, A549, MCF-7, and HeLa, with IC50 values of 1.20 μM, 2.09 μM, 1.56 μM, and 1.92 μM, respectively. Thus, Topoisomerase I inhibitor 4 holds promise for cancer research applications [1].

Glyoxalase I inhibitor 1 is a potent inhibitor of glyoxalase I (GLO1) (IC50: 26 nM).

Topoisomerase I (Compound ZML-14) inhibitor 3 induces HepG2 cell apoptosis and arrests cell cycle at G2 M phase. Topoisomerase I inhibitor 3 is an inhibitor of topoisomerase I that interact with topoisomerase I-DNA complex [1].

Glyoxalase I inhibitor 2 (compound 26) is a potent inhibitor of glyoxalase I (GLO1) with an IC50 of 0.5 μM, and has potential applications in depression and anxiety studies.

sEH inhibitor-5 is a potent inhibitor of sEH (soluble epoxide hydrolase) (IC50: 0.1 nM).

α-Synuclein inhibitor 5 is a potent inhibitor of α-Synuclein (α-Syn) aggregation across the blood-brain barrier (IC50: 1.22 μM), with 94.3% inhibition at 30 μM.

Flaviviruses-Inhibitor-I is several viruses belonging to the family of Flaviviridae inhibitor.

2’-O-Me-5-I-U-3’-phosphoramidite, a purine nucleoside analog, exhibits extensive antitumor activity primarily against indolent lymphoid malignancies through mechanisms such as DNA synthesis inhibition and apoptosis induction, among others [1].

Protein kinase inhibitor 5 sulfate hydrate, a potent TRK-A inhibitor, exhibits an IC50 of 1.8 nM and impairs cell viability [1].

HIF-1 inhibitor-5 (Compound 16e) is a potent HIF-1 inhibitor with an IC50 value of 2.38 μM, demonstrating significant anti-angiogenic potential [1].

MMP-8 Inhibitor I is a selective inhibitor of the neutrophil collagenase matrix metalloproteinase-8 (MMP-8) with an IC50 value of 4 nM.

MMP-9 MMP-13 Inhibitor I is a dual inhibitor of MMP-9 and MMP-13 with IC50 of 0.9 nM for both enzymes. It is over 20 times more selective for MMP-9 MMP-13 than for other MMPs.

c-Myc Inhibitor 5 (DA3) is a fluorescent bispurine compound with a long-chain bridge that selectively binds to the c-MYC G-quadruplex, exhibiting a dissociation constant (K D) of 16 μM. Unlike other G4-driven oncogenes, this inhibitor specifically suppresses c-MYC expression [1].

Topoisomerase I/II inhibitor 4 is a potent dual inhibitor of topoisomerase I (Topo I) and II (Topo II) with inhibitory effects on cell proliferation, invasion and migration, and induction of apoptosis, and can be used to study hepatocellular carcinoma.

Topoisomerase I inhibitor 2 (ZML-8) is a highly selective DNA topoisomerase I (Top1) inhibitor that impedes Top1 activity, causing DNA damage. It arrests the cell cycle at the G2 M phase and induces apoptosis, exhibiting anti-tumor effects [1].

Pim-1 kinase inhibitor 5 (Compound 4c) has an IC50 of 0.61 μM and exhibits cytotoxicity against cancer cell lines HepG2, MCF-7, PC3, and HCT-116, with IC50 values ranging from 6.95 to 20.19 μM [1].

KRAS G12C inhibitor 5 is a KRas G12C inhibitor. (Add a sentence that describes its primary function, mechanism, or application.)